# Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

> **NCT01930162** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Single Umbilical Cord Blood Transplantation
- Non-myeloablative Conditioning
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** HSC835

## Key facts

- **NCT ID:** NCT01930162
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-07
- **Primary completion:** 2016-08-29
- **Final completion:** 2016-08-29
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01930162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01930162, "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01930162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*